This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
LATS2 / Serine/threonine-protein kinase LATS2 · Western blot design guide
Design a Western Blot for LATS2
Real validated LATS2 Western blot protocols, expected-band and isoform facts, troubleshooting for weak or shifted signal, and recommended anti-LATS2 WB antibodies. Everything you need to plan the experiment before you commit precious samples.
Evidence assembled September 2026 · For research use; verify linked source records and product datasheet before use
LATS2 Western Blot Experimental Design Guide
Expected bands, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | ~120.1 kDa | |
| Observed band | ~150 kDa | |
| Gel | 8% (catalog A01352-1) | |
| Positive control | Cerebral cortex (IHC candidate; verify WB) +4 more | |
| Negative control | Appendix (IHC candidate; verify WB) |
Important caveats
Reasons your observed band may differ from the expected size.
| PTM | Phosphorylated | |
| Caveat | Phosphorylation-state controls | |
| Gene-set association | MSigDB Hallmark membership | |
| Isoform | 1 isoform(s) |
Section 1
Real Curated LATS2 Western Blot Protocols
The A01352-1 protocol combines labelled catalog values with standard starting conditions. Published comparisons retain their own sample, reagent and detection scope.
| Sample / lysate | human Hela, human 293T, human Caco-2 (catalog A01352-1) |
| Gel % | 8% (catalog A01352-1) |
| Load | 30 ug; reducing conditions (catalog A01352-1) |
| Transfer | a nitrocellulose membrane at 150 mA for 50-90 minutes (catalog A01352-1) |
| Membrane | nitrocellulose membrane (catalog A01352-1) |
| Blocking | 5% non-fat milk/TBS for 1.5 hour at RT (catalog A01352-1) |
| Primary antibody | A01352-1 · 1: 1000 (catalog A01352-1) |
| Primary incubation | overnight at 4°C (catalog A01352-1) |
| Secondary antibody | goat anti-rabbit IgG-HRP, 1:5000 (catalog A01352-1) |
| Secondary incubation | 1.5 hour at RT (catalog A01352-1) |
| Wash | TBS-0.1%Tween 3 times with 5 minutes each (catalog A01352-1) |
| Detection | ECL (catalog A01352-1) |
Section 2
What Is the Expected LATS2 Western Blot Band Size?
LATS2 is predicted at 120.1 kDa and observed at ~150 kDa in antibody QC; the cause of the difference is not established.
| Band near 150 kDa | Empirical LATS2 band in reducing whole-cell lysates; its migration above the predicted mass is unexplained. |
| Band near 120.1 kDa | Near the predicted sequence mass; identity requires validation. |
| Close doublet near the main band | Could reflect different phosphorylation states; distinct migration is unproven. |
| Weak band in a soluble fraction | LATS2 may be under-recovered because it also localizes to cytoskeletal and nuclear compartments. |
💡Expected LATS2 appearanceLATS2 has a predicted sequence mass of 120.1 kDa, while antibody QC detects ~150 kDa in reducing whole-cell lysates; the difference is unexplained, so confirm band identity with depletion controls.
| Predicted sequence mass | 120.1 kDa predicted; the empirical band is ~150 kDa, with no established cause for the difference. |
| AURKA-dependent phosphorylation at Ser83 | May affect apparent mobility; no shift is established. |
| Phosphorylation at Thr279 | May affect apparent mobility; no shift is established. |
| Phosphorylation at Ser380 | May affect apparent mobility; no shift is established. |
| Phosphorylation at Ser576 | May affect apparent mobility; no shift is established. |
| Phosphorylation at Thr1041 | May affect apparent mobility; no shift is established. |
| Situation | Likely cause | Next action |
|---|---|---|
| No band in lysate | LATS2 recovery may be limited by its cytoskeletal or nuclear localization. | Check extraction of those compartments and include a positive-control lysate. |
| Band higher than expected | The reported ~150 kDa band exceeds the 120.1 kDa prediction for an unknown reason. | Compare with the reported band and verify identity by LATS2 depletion. |
| Band lower than expected | A lower band has no established LATS2-specific explanation in the supplied features. | Check sample integrity and test whether the band decreases after LATS2 depletion. |
| Multiple bands | Different phosphorylation states are possible, but distinct bands are unproven. | Compare phosphatase-treated samples and confirm each candidate band by LATS2 depletion. |
| Weak or no signal | LATS2 may be poorly recovered from the sampled cellular compartment. | Check lysate loading and extraction, then compare with a positive-control lysate. |
| Fragments below expected size | Sample degradation is possible; no physiological LATS2 cleavage is listed. | Prepare fresh lysate with protease inhibitors and verify fragment identity by depletion. |
Experiment evidence
Western blot images showing LATS2 band
A01352-1 · LATS2
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for LATS2 Western blot
🧪HPA-IHC candidate guidance (verify in WB): For positive controls for LATS2 in Western blot, you can use cerebral cortex lysate, which HPA rates as highly positive.
Positive control: Cerebral cortex (IHC candidate; verify WB)
Negative control: Appendix (IHC candidate; verify WB)
Loading controls: Run GAPDH, β-actin, and a total-protein stain alongside the samples.
⚠️Feasibility: HPA reports high expression in cerebral cortex and no detection in appendix, making tissue controls feasible.
HPA tissue expression evidence for LATS2
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Higher expression tissues · candidate positive controls from IHC
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Cerebral cortex | neuropil | High | Protein (IHC) | HPA → |
| Stomach | glandular cells | High | Protein (IHC) | HPA → |
| Testis | spermatogonia cells | High | Protein (IHC) | HPA → |
| Breast | glandular cells | Medium | Protein (IHC) | HPA → |
| Caudate | glial cells | Medium | Protein (IHC) | HPA → |
Lower expression tissues · IHC evidence, not confirmed WB-negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Appendix | glandular cells | Not detected | Protein (IHC) | HPA → |
| Endometrium | cells in endometrial stroma | Not detected | Protein (IHC) | HPA → |
| Epididymis | glandular cells | Not detected | Protein (IHC) | HPA → |
| Heart muscle | cardiomyocytes | Not detected | Protein (IHC) | HPA → |
| Parathyroid gland | glandular cells | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced LATS2 Western Blot Tips
Deeper troubleshooting and optimisation questions for LATS2, answered from its protein features.
How should LATS2 band migration be interpreted?
Band shift · Use the separately labelled calculated mass and catalog-observed evidence above. A sequence annotation does not establish an observed migration shift. Verify target identity with orthogonal controls.
Could LATS2 isoforms explain multiple bands?
Isoforms · The supplied record lists one isoform and no alternative sequence. It therefore provides no isoform-based explanation for multiple bands. Assess additional bands independently rather than labeling them as LATS2 isoforms.
Which LATS2 phosphorylation sites matter when interpreting bands?
PTM · The listed UniProt sites are Ser83, phosphorylated by AURKA; Thr279; Ser380; Ser576; and Thr1041. These are UniProt coordinates and may differ from paper or antibody numbering. A site’s presence does not establish a visible shift; use a site-specific antibody or phosphatase comparison to investigate phosphorylation.
Does this guide establish induction of LATS2?
Induction · No general induction response is established by this guide. A pathway or gene-set association is not evidence of induction in a particular specimen. Verify the relevant treatment and control in a target-specific experiment.
What transfer method to use for LATS2 Western blot?
Transfer · Optimize transfer for a protein predicted at 120.1 kDa with a reported apparent band near 150 kDa. Check transfer in that size range using a marker and membrane stain. The supplied features do not establish whether wet or semi-dry transfer works better for LATS2.
How should blocking be optimized?
Blocking · Standard workflow guidance: follow the A01352-1 datasheet where specified. Otherwise compare 5% milk or 5% BSA in TBST; for a phospho-specific assay start with BSA. Optimize background and specific signal with matched controls.
How should total LATS2 be quantified across cell-cycle conditions?
Quantitation · Use matched samples and quantify the verified LATS2 band with a consistent normalization method. Because LATS2 is a phosphoprotein with cell-cycle-related localization, keep total-protein and phospho-specific measurements distinct. The supplied features do not establish that a change in phosphorylation reflects a change in total abundance.
Why might LATS2 appear near 150 kDa instead of 120.1 kDa?
Interpretation · The supplied predicted mass is 120.1 kDa, while the reported apparent band is about 150 kDa. LATS2 has five listed phosphorylation sites, but their presence alone does not explain or demonstrate this difference. Confirm band identity with an appropriate control before assigning the 150 kDa band to LATS2.
LATS2 is linked to mitosis and interacts with AURKA, which phosphorylates UniProt Ser83. Its reported location changes from centrosomes to spindle poles during mitosis. Compare matched cell-cycle conditions if examining phosphorylation or localization, but do not assume mitosis increases total LATS2 abundance.
The record lists no signal peptide, propeptide, alternative sequence, or glycosylation sites to account for a smaller form. Those features do not establish the identity of an unexpected band. Compare the band with a LATS2-specific depletion or other identity control before assigning it to LATS2.
LATS2 is linked to mitosis and interacts with AURKA, which phosphorylates UniProt Ser83. Its reported location changes from centrosomes to spindle poles during mitosis. Compare matched cell-cycle conditions if examining phosphorylation or localization, but do not assume mitosis increases total LATS2 abundance.
The record lists no signal peptide, propeptide, alternative sequence, or glycosylation sites to account for a smaller form. Those features do not establish the identity of an unexpected band. Compare the band with a LATS2-specific depletion or other identity control before assigning it to LATS2.
Boster reagents
LATS2 Western Blot Antibodies
Catalog antibodies with Western blot application and product-specific WB images. Evaluate suitability with the reported sample, controls and experimental conditions.
Real WB data
Anti-LATS2 Antibody
Cat # A01352-1
A01352-1 is a rabbit polyclonal anti-LATS2 antibody listed for human and mouse reactivity. Its Western blot image shows a band near 150 kDa in human whole-cell lysates, above the stated expected size of 120 kDa.
Which to pick: A01352-1 is the only listed option. Its Western blot image uses HeLa, 293T, Caco-2, and SIHA human lysates at 1:1000. Mouse reactivity is listed, but the supplied image documents human samples only.
Source: BosterBio LATS2 gene-info card — filtered to Western-blot-capable antibodies; each card shows that product's actual WB validation figure.
References
- UniProt Consortium. UniProt entry Q9NRM7.
- Human Protein Atlas. LATS2 tissue expression.
- PMC8027360 — target-verified WB comparison
- PMC7260745 — target-verified WB comparison
- PMC2958949 — target-verified WB comparison